1-5 of 5
Alexandra Muir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Tanya Siddiqi, Leslie L. Popplewell, Alexandra Muir, Ivana Melgar, Kirsten Orand, Brandy Gonzalez, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V Danilov
Journal: Blood
Blood (2022) 140 (Supplement 1): 6633–6634.
https://doi.org/10.1182/blood-2022-160157
Published: 2022
Journal Articles

A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Alexey V Danilov, Alexandra Muir, Ivana Melgar, Sandrine Puverel, Peter Sportelli, Hari P. Miskin, Lu Chen, Geoffrey Shouse
Journal: Blood
Blood (2022) 140 (Supplement 1): 3633–3634.
https://doi.org/10.1182/blood-2022-159805
Published: 2022
Journal Articles

A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Pallawi Torka, Swetha Kambhampati, Alexandra Muir, Kirsten Orand, Lynne Smith, Alex F. Herrera, Lionel Lewis, Francisco J. Hernandez-Ilizaliturri, Lu Chen, Alexey V. Danilov
Journal: Blood
Blood (2021) 138 (Supplement 1): 2433.
https://doi.org/10.1182/blood-2021-146345
Published: 2021
Journal Articles

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Tanya Siddiqi, Leslie L. Popplewell, Alexandra Muir, Ivana Melgar, Brandy Gonzales, Kirsten Orand, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V. Danilov
Journal: Blood
Blood (2021) 138 (Supplement 1): 3558.
https://doi.org/10.1182/blood-2021-149320
Published: 2021
Journal Articles

Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study

Tanya Siddiqi, Pamela Clay, Kate Murray, Navshina Shekh, Alexandra Muir, Steven T. Rosen, Steven Coutre
Journal: Blood
Blood (2021) 138 (Supplement 1): 3754.
https://doi.org/10.1182/blood-2021-154203
Published: 2021